Key Drivers
- Cash Generation
- High Leverage
- Thin Equity
AIAI Summary
BMY has shifted from a simple patent-cliff value trap to an execution-dependent transition story, with the growth portfolio now contributing more than half of revenue and strong cash flow supporting the dividend and pipeline, but the stock is only compelling if new assets can scale fast enough to offset the 2028 Eliquis/Opdivo hit given the leveraged balance sheet and limited margin for error.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Generation
- •High Leverage
- •Thin Equity
BMY generates strong earnings and cash flow with solid margins, but heavy leverage, negative tangible equity, and a moderate valuation make the investment case dependent on sustained cash generation and disciplined capital returns.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Support defense
- •Resistance test
BMY has improved from a choppy range into a modest uptrend over the last month, with higher lows and a breakout attempt above the mid-to-high $57s, but it still needs to hold $54–$55 support and clear $58–$59 resistance to confirm follow-through.
Sharp late-June drop followed by a strong two-day rebound suggests near-term volatility risk
Sentiment & News
Key News Insights:
- •Value Appeal
- •Growth Mix
- •Patent Pressure
Bristol Myers Squibb is being viewed as a dividend-rich value stock with improving growth products, but legacy drug erosion and patent risk still cap near-term upside.
The stock may stay supported by income and new-product momentum, but sustained gains likely depend on how quickly BMY offsets Eliquis and Opdivo erosion
Similar Companies in Healthcare
Other companies in the same sector with AI ratings